MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The review is undoubtedly well written although there are several other reviews on the same topic so i have some concerns on the novelty of the paper.

I liked the long section on therapeutic outcomes in NAFLD-related HCC but i would like to see also another section on the treatments to prevent the occurrence of HCC in NAFLD patients. In this regard cite the recent SRMA: PMID: 33721336 )

Some figures would improve the quality of the manuscript

Consider the use of the term MAFLD instead of NAFLD in the manuscript

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

The authors have reviewed NAFLD and HCC development: pathogenesis and treatment challenges.

As the title suggests, the literature reviews are well-organized and helpful to readers.

Minor points.

The international liver societies like AASLD and EASL have changed the terms regarding fatty liver disease nomenclature. Metabolic dysfunction associated steatotic liver disease (MASLD) is replaced term for NAFLD. Metabolic dysfunction-associated steatohepatitis (MASH) is also replaced term for NASH. Therefore, the terms should be changed according to it.

It is considered that there are no additional issues related to the manuscript.

Comments on the Quality of English Language

None.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

Comments and Suggestions for Authors

The revised version of the paper is OK. Thank you!